EYPT - EyePoint Pharmaceuticals GAAP EPS of -$1.16 misses by $0.54 revenue of $10.53M beats by $0.13M
- EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q4 GAAP EPS of -$1.16 misses by $0.54 .
- Revenue of $10.53M (-8.8% Y/Y) beats by $0.13M .
- Cash, cash equivalents and investments in marketable securities on December 31, 2022 totaled $144.6M.
- We expect the cash, cash equivalents and investments on hand on December 31, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
For further details see:
EyePoint Pharmaceuticals GAAP EPS of -$1.16 misses by $0.54, revenue of $10.53M beats by $0.13M